The European Patent Office (EPO) has published patent application EP4709353A1, detailing an "Injectable sustained release buprenorphine formulation." The application lists Michael Guarnieri as the sole applicant and inventor. This publication signifies the formal disclosure of the invention under patent law, making the details publicly available.

This patent publication does not impose new regulatory obligations on pharmaceutical companies or healthcare providers. However, it is relevant for entities involved in the research, development, or manufacturing of buprenorphine formulations, as it may impact intellectual property landscapes and future market exclusivity. Companies should monitor patent filings in their therapeutic areas of interest to understand potential competitive and licensing implications.